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Abstract: Mutations in APC promote colorectal cancer (CRC) progression through uncontrolled WNT
signaling. Patients with desmoplastic CRC have a significantly worse prognosis and do not benefit
from chemotherapy, but the mechanisms underlying the differential responses of APC-mutant CRCs to
chemotherapy are not well understood. We report that expression of the transcription factor prospero
homeobox 1 (PROX1) was reduced in desmoplastic APC-mutant human CRCs. In genetic Apc-mutant
mouse models, loss of Prox1 promoted the growth of desmoplastic, angiogenic, and immunologically silent
tumors through derepression of Mmp14. Although chemotherapy inhibited Prox1-proficient tumors, it
promoted further stromal activation, angiogenesis, and invasion in Prox1-deficient tumors. Blockade
of vascular endothelial growth factor A (VEGFA) and angiopoietin-2 (ANGPT2) combined with CD40
agonistic antibodies promoted antiangiogenic and immunostimulatory reprogramming of Prox1-deficient
tumors, destroyed tumor fibrosis, and unleashed T cell-mediated killing of cancer cells. These results
pinpoint the mechanistic basis of chemotherapy-induced hyperprogression and illustrate a therapeutic
strategy for chemoresistant and desmoplastic CRCs.
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Introduction
Colorectal cancer (CRC) is one of the leading causes of cancer- 
related mortality worldwide (1). Patients with stage III or IV CRC 
have a high risk of recurrence and are typically treated with sur-
gery and 5-FU–based adjuvant chemotherapy alone (stage III), 
or combined with targeted therapy such as anti-VEGF (α-VEGF) 
or α-EGFR antibodies (stage IV). Chemotherapy increases the 
overall survival by up to 15%, yet many patients do not respond 
or relapse, highlighting the need for the development of new ther-
apeutic strategies. Likewise, targeted blockade of the oncogenic 
EGFR pathway or VEGF-driven angiogenesis have shown effec-
tiveness in advanced CRC, but most clinical responses are tran-
sitory. Most recently, programmed cell death 1 (PD-1) immune 
checkpoint blockade was approved for the treatment of CRCs 
with defective mismatch repair. However, the treatment is not 
effective in patients with microsatellite-stable (MSS) CRC, which 
accounts for the majority of cases (2, 3). A better understanding 
of the mechanisms underlying primary and acquired resistance to 
current therapies in CRC and the development of novel combina-
torial approaches are urgently needed to improve the treatment of 
this common and lethal disease.
One of the key factors accounting for highly variable outcomes is 
the molecular heterogeneity of CRC. Recently, 2 molecular classifi-
cations were established: consensus molecular subtypes 1–4 (CMS1–
4), based on total tumor transcriptomes, and CRC-intrinsic subtypes 
(CRIS, CRIS-A–E), based on cancer cell transcriptomes (4–6). CMS1 
(14% of CRC cases) is characterized by microsatellite instability 
(MSI), high levels of mutations, strong immune cell activation, low 
WNT signaling, and a good prognosis; CMS2 (37%) is epithelium 
rich, with marked canonical WNT pathway activation and prolif-
erative signaling; CMS3 (13%) displays metabolic dysregulation 
and intermediate WNT signaling; CMS4 (23%) is characterized by 
low WNT signaling, a high proportion of stromal cells, prominent 
angiogenesis, and a poor prognosis (4). Causative molecular alter-
ations are more obvious in CMS1 and CMS3 groups, which show 
hypermutability (94% and 28%) and a high rate of BRAF (CMS1) 
or KRAS (CMS3) mutations. However, the spectrum of driver 
mutations (APC, KRAS, TP53) is similar in MSS CMS2 and CMS4 
subtypes, and it remains unclear why patients with CMS4 tumors 
have faster metastatic progression and shorter overall survival (4).
Mutations in APC promote colorectal cancer (CRC) progression through uncontrolled WNT signaling. Patients with 
desmoplastic CRC have a significantly worse prognosis and do not benefit from chemotherapy, but the mechanisms 
underlying the differential responses of APC-mutant CRCs to chemotherapy are not well understood. We report that 
expression of the transcription factor prospero homeobox 1 (PROX1) was reduced in desmoplastic APC-mutant human CRCs. 
In genetic Apc-mutant mouse models, loss of Prox1 promoted the growth of desmoplastic, angiogenic, and immunologically 
silent tumors through derepression of Mmp14. Although chemotherapy inhibited Prox1-proficient tumors, it promoted 
further stromal activation, angiogenesis, and invasion in Prox1-deficient tumors. Blockade of vascular endothelial growth 
factor A (VEGFA) and angiopoietin-2 (ANGPT2) combined with CD40 agonistic antibodies promoted antiangiogenic and 
immunostimulatory reprogramming of Prox1-deficient tumors, destroyed tumor fibrosis, and unleashed T cell–mediated 
killing of cancer cells. These results pinpoint the mechanistic basis of chemotherapy-induced hyperprogression and illustrate 
a therapeutic strategy for chemoresistant and desmoplastic CRCs.
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recently been shown to increase sensitivity to PD-1/programmed 
cell death ligand 1 (PD-1/PD-L1) immune checkpoint blockade 
in genetic models of CRC (14). In desmoplastic pancreatic ductal 
adenocarcinoma, tumor anticancer immunity can be efficiently 
unleashed through the activation of CD40 signaling (20, 21).
Here, we investigated the responses to chemotherapy and 
immunotherapy of prospero homeobox 1 (PROX1)- proficient 
(PROXhi) and PROX1-deficient (PROX1lo) models of MSS Apc- 
mutant intestinal tumors. PROX1 is a transcriptional repressor 
that is overexpressed in a subset of MSS CRCs with high WNT sig-
naling (22). Under physiological conditions, PROX1 specifies cell 
fate and maintains the expression of lineage-specific genes in lym-
phatic ECs, cardiomyocytes, hepatocytes, and certain neuronal 
populations (23–27). PROX1 is not expressed in normal intestinal 
stem cells and is ectopically induced in intestinal epithelium upon 
oncogenic transformation in response to supraphysiological and 
prolonged WNT activation (22). It promotes metabolic adaptation 
of transformed intestinal stem cells and enhances tumor growth 
in preclinical CRC models (28, 29). Here, we report that PROX1 
restrained stromal activation in WNThi tumors and licensed the 
chemosensitive phenotype. Surprisingly, we found that chemo-
therapy potentiates desmoplasia, angiogenesis, and aggressive 
growth of Prox1-deficient tumors and identified the metalloprote-
ase MMP14 as a target of PROX1 that promotes such a response. 
We further show that the combined blockade of angiogenesis 
and CD40-driven immune activation was an efficient alterna-
tive treatment approach that unleashed T cell–mediated killing 
of cancer cells in chemoresistant Apc-mutant tumors. We believe 
our results have broad implications for the development of novel 
therapies to treat APC-mutant MSS CRCs, which represent the 
majority of all CRC cases.
Results
High PROX1 expression is associated with a better prognosis and low 
stromal content in human CRCs. PROX1 is highly expressed in a 
subpopulation of CRC stem/progenitor cells (CSCs) in human 
WNThi MSS tumors, but not in WNTlo MSI tumors (28). We and 
others found that PROX1 sustains the metabolic fitness of CSCs 
and potentiates the growth of colon cancer cells in 3D organoid 
and mouse models (28, 29). To further study the clinical relevance 
of these observations, we analyzed the association of PROX1 with 
clinical outcomes in 444 patients from a prognostically annotated 
CRC gene expression data set (Gene Expression Omnibus [GEO] 
GSE39582) (30). Surprisingly, we found that high levels of PROX1 
were associated with improved overall survival (Figure 1A). Analy-
sis of pathways associated with PROX1 expression further showed 
that high PROX1 expression was positively correlated with WNT 
activation (Figure 1B), in agreement with previous data (28). 
Accordingly, PROX1 expression was highest in the WNThi CMS2 
group (Figure 1C). Our clinical outcome analysis differed from the 
results of a previous histopathological study (31), therefore, we 
also analyzed tumors classified according to 5 intrinsic subtypes 
(6) and found that PROX1 expression was significantly higher in 
the WNThi CRIS-C, -D, and -E subtypes compared with expression 
in the poor-prognosis CRIS-B subtype (Figure 1D).
PROX1 expression was negatively correlated with a stromal 
gene signature (Figure 1E), consistent with decreased PROX1 
Comparison of CMS and CRIS classifications revealed that 
most CMS1 and CMS3 tumors belong to the CRIS-A subtype, 
enriched for MSI or KRAS mutations, whereas the CMS2 subtype 
comprises 3 CRIS groups with high WNT signaling but also dis-
tinct features: CRIS-C has high EGFR pathway activity; CRIS-D is 
enriched for IGF2 overexpression, and CRIS-E has Paneth cell–like 
characteristics. A CRIS-B subtype was also identified, with TGF-β 
pathway activation, epithelial-to-mesenchymal transition (EMT), 
and poor prognosis, whereas the CMS4 subtype was distributed 
among all CRIS subtypes, confirming previous observations that 
the CMS4 transcriptome is dominated by stromal contribution 
(5–9). Analysis of clinical responses to adjuvant chemotherapy in 
patients with stage III CRC revealed a benefit for epithelium-rich 
CMS2 and CMS3 subgroups, but not for the CMS1 or CMS4 sub-
groups (7, 10, 11). However, the molecular mechanism underlying 
this differential response pattern is not fully understood.
In addition to molecular subtypes, a high degree of CD3+ and 
CD8+ T cell infiltration into the primary tumor is associated with 
a better prognosis in both MSI and microsatellite stable (MSS) 
CRCs, where it strongly predicts the time to recurrence, overall 
survival, and disease-free survival (12). High T cell infiltration is 
associated with MSI status in CRCs, and it is also observed in 20% 
of MSS CRC tumors. The molecular causes that mediate T cell 
exclusion in the majority of MSS CRCs are not completely under-
stood. Such exclusion is at least in part a result of the significantly 
lower mutational burden of MSS CRCs (13), however, additional 
active mechanisms preventing intratumoral cytotoxic T lympho-
cyte (CTL) accumulation and activation probably exist, and anti-
tumor T cell immunity can be elicited in preclinical models of MSS 
CRC (14). Given that current checkpoint inhibitors are ineffective 
in most patients with MSS CRC, it is essential to understand the 
interactions between cancer cells and the tumor microenviron-
ment (TME) of different CRC subtypes in order to develop new 
targeted interventions capable of shifting the balance toward a 
tumor-rejecting response.
Targeting the tumor blood vasculature has emerged as a prom-
ising approach to achieve this goal. Continuous production of the 
angiogenic and vessel-destabilizing factors VEGFA and angio-
poietin-2 (ANGPT2) impairs the alignment of tumor endothelial 
cells (ECs) and pericytes, increases vessel permeability, and reduc-
es tumor perfusion. Such impaired tumor blood vessels promote 
an immunosuppressive environment by hindering the efficient 
extravasation and functioning of CTLs (15). The reversal of tumor 
vessel abnormality or “vascular normalization” has been shown 
to increase the penetration of activated immune cells (16). In a 
murine breast cancer model, the simultaneous blockade of VEGFA 
and ANGPT2 using the bispecific blocking antibody A2V was 
highly effective in normalizing the tumor vasculature, reprogram-
ing the TME, and increasing the efficacy of immune checkpoint 
blockade (17). Also, angiogenic blockade promoted the formation 
of high endothelial venule–like (HEV-like) vessels and improved 
the response to immune therapies in a genetic model of pancreatic 
neuroendocrine tumor (18, 19).
Cancer-associated fibroblasts (CAFs) are another essential 
TME component that both foster tumor angiogenesis and directly 
limit a productive antitumor response (15). Therapeutic block-
ade of the profibrotic and immunosuppressive factor TGF-β has 
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into the cecum. With this approach, ectopic hyperactivation of 
WNT signaling occurs in a limited number of intestinal epithelial 
cells and leads to the development of a single, large, and frequently 
invasive cecal tumor that does not interfere with intestinal tran-
sit, thus allowing for the study of advanced tumors (Figure 2A and 
Supplemental Figure 1A).
Abnormally high WNT signaling is a main driver of cancer cell 
proliferation, tumor growth, and dedifferentiation in Apc-mutant 
CRC models (32, 33). We found that APP mouse tumors were sig-
nificantly smaller than AP mouse tumors 4 weeks after tamoxifen 
microinjection (Figure 2B), in agreement with previous observa-
tions in Apcmin/+ Prox1fl/fl villin-Cre adenomas (22). Expression of 
the WNT target genes leucine-rich repeat–containing G protein–
coupled receptor 5 (Lgr5), lymphoid enhancer binding factor 1 
(Lef1), ring finger protein 43 (Rnf43), and Eph receptor B2 (EphB2) 
(34–36) was decreased but not completely abolished upon loss of 
expression in desmoplastic CMS4 CRCs (Figure 1C). For an inde-
pendent validation of these data, we quantified PROX1 protein 
and stromal content of 114 primary MSS CRCs. We found that 
tumors with low nuclear PROX1 levels had greater stromal con-
tent (Figure 1, F and G, and Supplemental Table 1; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI129558DS1). These data indicate that low PROX1 expression 
is associated with reduced WNT activation, high stromal content, 
and worse clinical outcomes in human MSS CRCs.
Inactivation of Prox1 attenuates WNT signaling in mouse intes-
tinal tumors. We used Apcfl/fl Tp53fl/fl villin-CreERT2 (AP) and Apcfl/fl 
Tp53fl/fl Prox1fl/lf villin-CreERT2 (APP) mice, in which Apc, Tp53, and 
Prox1 can be conditionally inactivated in the intestinal epithelium 
to induce tumors, to determine whether Prox1 expression in cancer 
cells regulates tumor stromal content and properties. We induced 
tumors in both AP and APP mice by microinjection of tamoxifen 
Figure 1. High PROX1 expression is associated with better clinical outcomes and low stromal content. (A) Kaplan-Meier overall survival curves for 
patients with high or low PROX1 levels in MSS CRC tumors (GEO GSE39582; n = 444). Progression-free survival showed the same trend but did not reach 
significance (P = 0.3). (B) PROX1 expression correlation with WNT pathway activation in MSS CRCs (GSE39582; n = 444). Dashed line indicates the locally 
estimated scatterplot smoothing (LOESS) fit. (C) PROX1 expression in CRC CMS subgroups (GSE39582; n = 409). CMS1 MSI-like (n = 21); CMS2 high WNT 
signaling (n = 217); CMS3 KRAS-mutant and metabolic alterations (n = 63); CMS4 TGF-β–driven stromal and angiogenic activation (n = 108). P < 0.001, by 
1-way ANOVA with Tukey’s multiple comparisons test. P < 0.001, for CMS2 verus CMS1; P = 0.001, for CMS2 versus CMS3; P = 0.003, for CMS2 versus CMS4. 
(D) PROX1 expression in intrinsic CRIS subtypes. CRIS-A: BRAF- or KRAS-mutated, secretory (n = 88); CRIS-B TGF-β signaling, EMT features (n = 59); 
CRIS-C KRAS WT, high ERBB/EGFR pathway activity, MYC copy number gains (n = 119); CRIS-D: high WNT, IGF2 amplification, and FGFR autocrine stim-
ulation (n = 96); CRIS-E: high WNT, Paneth-like phenotype, and TP53-mutations (n = 82) in GSE39582 (n = 444). P < 0.001, by 1-way ANOVA with Tukey’s 
multiple comparisons test. (E) PROX1 expression negatively correlated with a tumor stromal signature in MSS CRCs (GSE39582; n = 444). The stromal gene 
signature is from ref. 80. Enrichment was computed using single-sample GSEA (81). Dashed line indicates the linear regression fit. (F) Scatterplot of the 
negative correlation between scores for PROX1 protein nuclear expression levels in tumor cells and for stromal content over the total tumor area, in MSS 
primary CRC samples (n = 114). (G) Representative images of CRC adenocarcinomas with high and low PROX1 scores. PROX1 staining  (brown) and DNA 
counterstaining (blue) are shown. Scale bars: 200 μm.
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Accordingly, mRNA levels of the CAF markers and TGF-β target 
genes fibroblast activation protein α (Fap), periostin (Postn), and 
serpin family E member 1 (Serpine1, also known as Pai1) (39) were 
significantly increased (Supplemental Figure 1E). Consistent with 
the RNA-Seq data, APP tumors displayed a denser and more intri-
cate blood microvascular network, whereas sparse and large blood 
vessels were observed in AP tumors (Figure 2, F and G). AP tumors 
displayed areas of high intraepithelial infiltration by CD8+ T cells, 
which were absent in the majority of APP tumors, indicative of 
immune exclusion (Figure 2, H and I).
We computed an enrichment score in human MSS CRCs on 
the basis of genes differentially expressed in APP versus AP tumors 
(APP signature) and found that the transcriptomes of the PROX1lo 
human MSS CRCs were enriched for the APP signature (Figure 
2J). Taken together, these results indicate that in mouse intesti-
nal tumors, loss of Prox1 in cancer cells promotes desmoplasia, 
angiogenesis, and T cell exclusion, which are associated with poor 
prognosis in human CRCs.
Prox1 loss generates desmoplastic tumors in the presence of acti-
vated KRAS. In addition to APC and TP53, KRAS is mutated in a 
significant proportion of CRCs. Constitutive KRAS activation 
confers an additional growth advantage to APC-mutant can-
cer cells and promotes resistance to EGFR-targeted therapies 
in patients with CRC (40). We analyzed the growth of intestinal 
organoids isolated from Apcfl/fl KrasLSL-G12D Tp53fl/fl villin-CreERT2 
(AKP) and Apcfl/fl KrasLSL-G12D Tp53fl/fl Prox1fl/fl villin-CreERT2 (AKPP) 
mice. Prox1 inactivation reduced the number of organoids that 
formed in Matrigel from AKPP cells (Figure 3A). These organoids 
had reduced cell proliferation rates (Supplemental Figure 2A) and 
grew as large, simple cysts, whereas most AKP organoids formed 
complex 3D structures (Figure 3B). The analysis of WNT target 
genes in AKPP organoids showed partial attenuation of WNT sig-
naling but no induction of differentiation (Figure 3C), consistent 
with APP tumor phenotypes (see above) and our previous findings 
in KRAS-mutant human CRC cell lines (28). Therefore, Prox1 loss 
blunted cancer cell–autonomous growth also in the presence of 
strong KRAS oncogenic signaling.
Prox1-deficient AKPP organoids implanted s.c. displayed rapid 
outgrowth after a long latency phase, indicating tumor adaptation 
to PROX1 deficiency (Figure 3D). This result was not due to clonal 
selection or acquisition of additional mutations, as organoids 
derived from primary tumors displayed similarly delayed growth 
kinetics upon ex vivo culturing or secondary implantation in mice 
(Supplemental Figure 2B). Large primary AKPP tumors (resected 
on day 93 after implantation) had increased production of the 
stromal proteins periostin, tenascin C, and α-SMA, increased 
stromal content, and increased expression of the CAF markers 
and TGF-β target genes Fap, Postn, Pai1, connective tissue growth 
factor (Ctgf), and osteopontin (Opn) (Figure 3E and Supplemental 
Figure 2, C and D), compared with AKP tumors (resected on day 
26 after implantation).
Increased accumulation of tumor stroma may be a result of 
delayed growth of AKPP tumors. To rule out this possibility, we 
implanted fewer AKP organoids and obtained comparable tumor 
growth kinetics with AKPP tumors. We then analyzed small size-
matched AKP and AKPP tumors, which were resected on days 
40 and 48 after implantation, respectively. Even in this setting, 
Prox1 (Figure 2B and Supplemental Figure 1B), indicating partial 
inhibition of WNT signaling. Interestingly, the WNT-dependent, 
cancer-specific V6 isoform of the hyaluronan receptor CD44 (37) 
was strongly upregulated in APP tumors (Supplemental Figure 
1, B and D). CD44V6 is a marker of CRC tumor–initiating cells 
that was previously shown to drive CRC invasion and metastasis 
(38). Unexpectedly, expression of keratin 20 (Krt20), a marker 
for enterocyte differentiation, was not rescued by Prox1 loss 
(Figure 2B and Supplemental Figure 1, B and C). Compared with 
AP cancer cells, APP cancer cells had a decreased proliferation 
index, as assessed by expression of the proliferation genes Ki67 
and cyclin B1 (Ccnb1) (Supplemental Figure 1B). These results 
suggest that Prox1 loss in APP tumors skews the expression of 
WNT-dependent genes and attenuates WNT signaling without 
inducing differentiation.
Inactivation of Prox1 generates desmoplastic, angiogenic, and 
T cell–excluded tumors. Comparison of tumor transcriptomes by 
RNA-Seq analysis revealed significant enrichment of transcripts 
related to EMT, angiogenesis, myogenesis and oxidative phos-
phorylation, and downregulation of transcripts related to the 
adaptive immune response in APP versus AP tumors (Figure 2C). 
Enrichment in EMT and angiogenesis transcripts is a feature of 
human desmoplastic CRCs that reflects expansion of the stromal 
cell compartment (8, 9). Staining for α–smooth muscle actin 
(α-SMA), which is expressed in cancer-associated fibroblasts 
(CAFs) and myofibroblasts, the epithelial marker E-cadherin, 
and the proliferation marker phosphohistone H3 (PH3), revealed 
increased stromal cell content and correspondingly lower epi-
thelial cell content and proliferation in APP compared with AP 
tumors, indicative of increased desmoplasia (Figure 2, D and E). 
Figure 2. Inactivation of Prox1 generates desmoplastic, angiogenic, and T 
cell–excluded tumors. (A) Apcfl/fl Tp53fl/fl villin-CreERT2 (AP) and Apcfl/fl Tp53fl/fl 
Prox1flfl villin-CreERT2 (APP) tumor models used in the study. (B) Appearance 
and weights of tumors and WT cecum and quantitative reverse transcrip-
tion PCR (qRT-PCR) data for Lgr5 and Krt20. AP (n = 22); APP (n = 15); WT 
(n = 7). qRT-PCR data were normalized to the AP mean. AP or APP (n = 
9); WT (n = 4). Scale bars: 4 mm. (C) Pathways enriched in APP versus AP 
transcriptomes (n = 6 per genotype). NES, normalized enrichment score. 
(D) APP tumors were desmoplastic. 3D reconstructions of tumor and WT 
cecum thick slices. Images show staining for PH3 (green), α-SMA (red), and 
E-cadherin (white). Scale bars: 50 μm. (E) Quantification of proliferation of 
stromal and tumor epithelial cells. The α-SMA+ area from D was normal-
ized to the total tumor area and the AP mean. For the α-SMA+ area: AP 
(n = 10); APP or normal cecum (n = 7). For Ki67+ colocalization: AP or APP 
(n = 6); normal cecum (n = 4). (F) 3D vascular reconstructions from tumor 
slices. Images show staining for CD31 (green) and E-cadherin (white). Scale 
bars: 50 μm. (G) Quantification of vascular parameters and expression of 
the endothelial marker Cdh5. AP (n = 10); APP (n = 7); normal cecum (n = 7). 
AP or APP (n = 9); WT (n = 4). Data were normalized to the AP mean. (H) 
Reduced CD8+ T cell infiltration into APP tumors. Images show staining for 
CD8+ T cells (green), VE-cadherin (red), and E-cadherin (white). Scale bars: 
50 μm. (I) Quantification of CD8+ T cells. AP (n = 10); APP (n = 6); normal 
cecum (n = 7). (J) APP signature is enriched in PROX1-low human CRCs. 
Enrichment of the APP versus AP signature in human CRCs (GSE39582; 
n = 444) was computed using Z scores. Dashed line indicates the linear 
regression fit. Data represent the mean ± SD. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 
0.001, and ****P ≤ 0.0001, by 1-way ANOVA with Tukey’s multiple compar-
isons test (B, E, and G) and grouped analysis by 2-way ANOVA with Tukey’s 
multiple comparisons test (E).
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AKPP tumors showed increased α-SMA+ stromal cell abundance 
(Supplemental Figure 2E), indicating that desmoplasia is PROX1 
dependent but tumor size independent. The proliferation of 
cancer cells was lower in AKPP tumors than in AKP tumors, irre-
spective of tumor size. We examined tumor margins and found 
a greater number of prominent invading cancer cell strands and 
increased proliferation of α-SMA+ stromal cells in AKPP tumors 
than in AKP tumors (Figure 3F and Supplemental Figure 2F). Col-
lectively, these data demonstrate that genetic loss of Prox1 gen-
erates slow-growing but more invasive and desmoplastic tumors, 
regardless of the presence of mutant Kras.
Fibroblasts and high tissue stiffness support the growth of 
Prox1-deficient tumors. Prox1-deficient AKPP organoids expressed 
higher levels of the profibrotic factors TGF-β1 (Tgfb1), platelet- 
derived growth factor C (Pdgfc), heparin-binding EGF-like growth 
factor (Hbegf), Ctgf, Opn, and IL-1β (Il1b) (Figure 3G), which may 
contribute to the promotion of expansion and activation of fibro-
blasts in tumors. Indeed, normal intestinal fibroblasts cocultured 
with AKPP organoids acquired a CAF-like phenotype charac-
terized by enhanced expression of α-SMA (Acta2), Fap, Postn, 
Ctgf, and Pai1, compared with fibroblasts cocultured with AKP 
organoids. AKPP-conditioned fibroblasts had greater prolifer-
ation, as determined by expression of Ki67 and Ccnb1 (Figure 
3H and Supplemental Figure 2G). Additionally, AKPP organoids 
also enhanced the expression of Tgfb1, matrix metalloproteases, 
inflammatory cytokines, and proangiogenic Vegfa in fibroblasts 
(Supplemental Figure 2G).
To determine whether fibroblasts accelerate the progression 
of Prox1-deficient tumors, we coimplanted AKP or AKPP organ-
oids together with fluorescent intestinal fibroblasts isolated from 
mTmG+ mice, in which all cells express the membrane-targeted 
tdTomato protein (41). The transplanted fibroblasts significantly 
enhanced the growth of AKPP but not AKP tumors (Figure 3I). 
Moreover, the exogenous fibroblasts persisted in AKPP but not 
AKP tumors, as shown by the presence of tdTomato+ cells (Figures 
3J). Of interest, exogenous fibroblasts enhanced cell proliferation 
only in the AKPP tumors, as shown by Ki67 staining (Figure 3, K 
and L, and Supplemental Figure 2H). These results support the 
notion that Prox1-deficient tumors promote a profibrotic TME that 
in turn sustains the growth of Prox1-deficient cancer cells.
We next examined the effects of intestinal fibroblasts on AKP 
and AKPP organoids. Because CAF-mediated extracellular matrix 
(ECM) deposition and increased tumor stiffness promote tumor 
growth (42), we cultured organoids in synthetic hydrogels with a 
stiffness similar to that of either normal intestine (1.3 kPa) or CRC 
stroma (2.7 kPa), as described previously (43), in the presence or 
absence of fibroblasts. We found that AKPP cells formed smaller 
organoids in synthetic hydrogels than in Matrigel (0.4 kPa) (Fig-
ure 3, M and B above). However, the addition of fibroblasts or 
high stiffness partly rescued, and their combination fully restored, 
the growth of AKPP organoids (Figure 3M and Supplemental Fig-
ure 2I). Conversely, fibroblasts and stiffness had modest, if any, 
effects on the growth of AKP organoids. Thus, both fibroblast- 
derived factors and increased tumor stiffness probably contribute 
to the promotion of AKPP tumor growth.
Chemotherapy promotes stromal activation and progression of 
Prox1-deficient tumors. 5-FU–based adjuvant chemotherapy is the 
standard of care for CRC and improves patient survival; however, 
a substantial proportion of the patients either do not respond to 
this treatment or relapse (2). To determine whether PROX1 regu-
lates responses to chemotherapy, we tested 5-FU or cisplatin as a 
control agent in AKP and AKPP organoids. Prox1-deficient AKPP 
organoids were less sensitive to 5-FU, an antimetabolite, than 
were AKP organoids, whereas AKP and AKPP organoids were 
similarly sensitive to cisplatin, which acts via a DNA cross-linking 
mechanism (Supplemental Figure 3A).
We next investigated the response of s.c. AKP and AKPP 
tumors to chemotherapy. In order to obtain AKP and AKPP 
tumors with comparable growth rates, we injected an excess 
of AKPP organoids and initiated the treatment when tumors 
reached approximately 130 mm3 in size (Figure 4A). Both 5-FU 
and cisplatin rapidly arrested the growth of AKP tumors, how-
ever, they did not affect AKPP tumors. At the end of the exper-
iments, the weight of treated AKP tumors was significantly 
reduced, whereas no difference was observed between the con-
trol and treated AKPP tumors (Figure 4A). Microscopic analysis 
showed that chemotherapy inhibited cancer cell proliferation in 
the core of AKP tumors (Supplemental Figure 3B), leading to sig-
nificant central necrosis, but we observed no such effects in AKPP 
tumors, which had low cancer cell proliferation and high necrosis 
at baseline (Supplemental Figure 3B). We observed major dif-
ferences in the tumor margins. Chemotherapy inhibited cancer 
cell proliferation and reduced peritumoral vascular density at the 
margins of the AKP tumors, whereas the AKPP tumor margins 
Figure 3. Prox1 loss generates desmoplastic tumors in the presence of 
activated Kras. (A) Reduced clonogenic capacity of Prox1–/– intestinal stem 
cells. Apcfl/fl KrasLSL-G12D Tp53fl/fl villin-CreERT2 (AKP) and Apcfl/fl KrasLSL-G12D 
Tp53fl/fl Prox1fl/fl villin-CreERT2 (AKPP) organoids (n = 12 per genotype). (B) 
AKP and AKPP organoids. Upper row shows Matrigel disks with organoids. 
Scale bars: 1.2 mm. Lower row shows H&E-stained organoid sections. 
Scale bars: 20 μm. Arrow indicates epithelial polarization loss. (C) WNT 
signaling and differentiation in AKP and AKPP organoids. Graph shows 
qRT-PCR for the indicated genes, and data are presented in a heatmap  
(n = 5). (D) PROX1 loss delayed tumor development. Mice were injected 
s.c. with 50 AKP or AKPP organoids. AKP, n = 5; AKPP, n = 6. (E) Masson’s 
trichrome staining of advanced tumors. Scale bars: 50 μm. (F) Increased 
stromal reaction and invasion in AKPP tumor margins. Images in top row 
show staining for PROX1 (green), E-cadherin (red), Ki67 (white), and DNA 
(blue). Images in bottom row show staining for POSTN (green), CD44V6  
(red), α-SMA (white), and DNA (blue). Scale bars: 50 μm. (G) AKPP organ-
oids produced profibrotic factors. Heatmap of the indicated genes (n = 
5). (H) AKPP organoids promoted fibroblast proliferation. Ki67 and Ccnb1 
expression by qRT-PCR. Data were normalized to the control mean (n = 6). 
(I) Tumor growth curves and weights. Mice were implanted with 50 AKP or 
300 AKPP organoids ± 5000 tdTomato+ intestinal fibroblasts (Fibro.)  
(n = 7). (J) AKPP cells sustained fibroblasts. Images show control and  
tdTomato+ (red) fibroblast–coinjected tumors. Scale bars: 2 mm. (K) Fibro-
blast coimplantation effects on tumor desmoplasia, PROX1 expression, 
and cell proliferation. Images show staining for PROX1 (green), α-SMA 
(red), Ki67 (white), and DNA (blue). Scale bars: 50 μm. (L) Quantification of 
the data shown in K. α-SMA+ and Ki67+ areas were normalized to the total 
tumor area and the AKP mean. (M) Fibroblast and tissue stiffness effect 
on organoids. Organoids with or without tdTomato+ fibroblasts in hydro-
gels with normal mucosa (1.3 kPa) or tumor (2.7 kPa) stiffness. Scale bars: 
1.2 mm. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001, by Student’s t test (A  
and C) or 1-way (H and L) or 2-way (I) ANOVA with Tukey’s multiple com-
parisons test, scatterplot, or mean ± SD.
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nuclear accumulation of phosphorylated STAT3 (p-STAT3) (Sup-
plemental Figure 3G). In summary, our results in both s.c. and 
autochthonous tumor models indicate that chemotherapy is highly 
effective in WNThiPROX1hi tumors. However, chemotherapy pro-
motes TGF-β–dependent fibroblast activation and production 
of angiogenic and protumoral factors in PROX1lo desmoplastic 
tumors and is thus detrimental to the outcome.
The PROX1 target gene Mmp14 induces tumor fibrosis and chemo-
resistance. PROX1 is a transcriptional repressor shown previously to 
directly repress annexin A1 (ANXA1) in Apc-deficient mouse intes-
tinal stem cells (29) and matrix metalloproteinase 14 (MMP14) in 
human liver, colon, and breast cancer cell lines (48). Accordingly, 
the expression of both genes was increased in cultured Prox1- 
deficient organoids and tumors (Figure 5A). In human CRC sub-
types, the highest MMP14 levels were observed in desmoplastic 
CMS4 tumors, whereas ANXA1 was prominent in both CMS1 and 
CMS4 tumors (Figure 5B). 5-FU further enhanced the expression 
of Mmp14 but not Anxa1 in Prox1-deficient organoids and tumors, 
along with expression of the profibrotic factors Tgfb1, Pdgfc, Hbegf, 
and Il1b (Figure 5C and Supplemental Figure 4, A and B).
To investigate whether ANXA1 or MMP14 were implicated in 
inducing the desmoplastic phenotype of Prox1-deficient tumors, 
we generated Anxa1- or Mmp14-overexpressing AKP organoids 
(ANXA1-AKP and MMP14-AKP, respectively) and, as a control, 
organoids expressing a nonsignaling form of the low-affinity nerve 
growth factor receptor (dlNGFR-AKP) (Supplemental Figure 4C). 
Overexpression of either protein did not affect the growth of 
organoids in vitro or the expression of WNT target genes (Supple-
mental Figure 4C). Upon s.c. injection, ANXA1-AKP and control 
dlNGFR-AKP tumors had similar growth rates, however, MMP14-
AKP tumors grew at a significantly slower rate (Figure 5D). Histo-
logical analysis revealed that overexpression of MMP14 was asso-
ciated with stromal cell proliferation and expansion, prominent 
angiogenic response, and reduced cancer cell proliferation (Figure 
5, E and F, and Supplemental Figure 4D). These results were fur-
ther corroborated by mRNA analysis of stromal and angiogenesis 
markers (Supplemental Figure 4E). MMP14-AKP tumors lacked 
the central necrosis observed in AKPP tumors and displayed no 
change in WNT signaling (Supplemental Figure 4E), indicating 
partial phenocopying of Prox1-deficient tumors.
We next examined whether MMP14 overexpression was suf-
ficient to confer tumor resistance to chemotherapy. 5-FU arrested 
the growth of control tumors but had no inhibitory effects on 
MMP14-AKP tumors (Figure 5G). Similar to the results in AKPP 
tumors, 5-FU did not affect cancer cell proliferation and further 
increased fibrosis and angiogenesis in MMP14-AKP tumors (Fig-
ure 5, H–J, and Supplemental Figure 4F). We also observed that 
transgenic MMP14 in cancer cells induced endogenous MMP14 
expression in stromal cells, an effect that was heightened by 
chemo therapy (Figure 5H and Supplemental Figure 4G). Together, 
these results suggest that tumor desmoplasia, angiogenesis, and 
resistance to chemotherapy induced by loss of Prox1 are mediated 
through the derepression of its direct target MMP14.
Reprogramming the angiogenic and immune microenviron-
ment restrains the growth of chemoresistant Prox1-deficient tumors. 
The aforementioned data indicate that chemoresistance of APP 
tumors is associated with a highly angiogenic and T cell–excluded 
showed high fibroblast proliferation, sustained vascularization, 
and exacerbated invasion (Figure 4, B and C, and Supplemental 
Figure 3C), with occasional intravasation of cancer cells into peri-
tumoral blood vessels (Supplemental Figure 3D), which we never 
observed in AKP tumors. Together, these results suggest that loss 
of Prox1 protects tumors from the effects of chemotherapy.
We next studied the effects of chemotherapy on autochtho-
nous (tamoxifen-induced) AP and APP tumors. 5-FU significantly 
reduced AP tumor size, however, it unexpectedly enhanced the 
growth of APP tumors (Figure 4D). In analogy with observations 
in the s.c. models, 5-FU induced cell death and reduced cancer 
cell proliferation in AP but not APP tumors (Figure 4, E and F). 
Importantly, both fibroblast proliferation and angiogenesis were 
further increased in 5-FU–treated APP tumors (Figure 4, F–H). In 
addition to CAF and angiogenesis markers, we found that Il1b and 
Ly6g were also induced, indicating increased inflammation and an 
influx of neutrophils (Supplemental Figure 3E).
Previous studies demonstrated that 5-FU increases TGF-β 
release and signaling (44). We then compared the effects of 
TGF-β1 or a clinically relevant (2.5 µm) of 5-FU (45) on cultured 
intestinal fibroblasts. We observed that 5-FU reduced fibroblast 
proliferation but promoted the expression of Tgfb1, as well as sev-
eral TGF-β target genes such as Pai1, Fap, and Acta2 (α-SMA) (Fig-
ure 4I). The effects of 5-FU on stromal cell activation were compa-
rable to those of TGF-β1. 5-FU also enhanced the expression of the 
proangiogenic and proinflammatory cytokines Vegfa, Il1b, and Il6. 
IL-6 is an upstream regulator of JAK/STAT3 signaling, which was 
previously shown to sustain colon cancer cell survival and WNT 
activation (46, 47). In the tumors, 5-FU did not alter the expression 
of WNT target genes (Supplemental Figure 3F), but both cancer 
and stromal cells in 5-FU–treated APP tumors displayed increased 
Figure 4. Prox1-deficient tumors are chemoresistant. (A) Tumor response 
to chemotherapy. Mice were implanted s.c. with 50 AKP or 300 AKPP 
organoids, and treatment with 5-FU or cisplatin was initiated when the 
mean volume of the tumors reached 130 mm3 (n = 7). (B) Chemotherapeu-
tic effect on tumor margins. Images show staining for PH3 (green), α-SMA 
(red), and E-cadherin (white). Scale bars: 50 μm. (C) Quantification of cell 
death, proliferation, and angiogenesis for the images in B. Cell death is 
indicated as the percentage of necrotic tumor glands. Other data are indi-
cated by the fold change versus the AKP control mean. Cis, cisplatin. (D) 
Macroscopic appearance of control- and 5-FU–treated AP and APP tumors 
and tumor weights at sacrifice. AP control, n = 7; AP 5-FU, n = 6; APP con-
trol, n = 4; APP 5-FU, n = 5. Scale bars: 2  mm. (E) 5-FU effects on tumor 
desmoplasia and cancer cells. Images show staining for PH3 (proliferation, 
green), α-SMA (fibroblasts, red), and E-cadherin (tumor cells, white). 
Scale bars: 50 μm. (F) Quantification of tumor cell proliferation and death. 
α-SMA+, PH3+E-cadherin+, and PH3+α-SMA+ areas were quantified and 
normalized to total tumor E-cadherin+ or α-SMA+ areas and the AP control 
mean. Cell death is shown as a percentage of necrotic tumor glands. (G) 
5-FU effect on angiogenesis. CD31+ vessel density is presented as the fold 
change versus the AP control mean. (H) Images show staining for CD31 
(green), α-SMA (red), E-cadherin (white), and DNA (blue). Scale bars:  
50 μm. (I) 5-FU suppressed proliferation and promoted the expression of 
CAF markers and fibrotic ligand in cultured fibroblasts. A heatmap of the 
indicated genes is shown. Intestinal fibroblasts were cultured for 24 hours 
in the presence of 2.5 μM 5-FU, 50 ng/mL TGF-β1, or control (n = 3). Data 
represent the mean ± SD. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P 
≤ 0.001, by 1-way (scatterplots) or 2-way (growth curves) ANOVA with 
Tukey’s multiple comparisons test. N, necrosis.
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combined treatment, but not aCD40 monotherapy, enhanced 
blood vessel coverage by α-SMA+ mural cells and increased the 
caliber of the remaining blood vessels. To evaluate vascular func-
tionality, we analyzed tumor hypoxia by staining for pimonida-
zole adducts. We found low levels of hypoxia in control AP and 
APP tumors, which were not modified by the treatment (Supple-
mental Figure 5, C and D). These data indicate that AP and APP 
tumors were well perfused at baseline and that the main effect of 
A2V in these models was the promotion of vascular maturation. 
In APP tumors, aCD40 monotherapy did not obviously alter the 
tumor stroma, whereas A2V reduced stromal cell content and the 
expression of the activation marker α-SMA in CAFs and myofibro-
blasts (Figure 6, B and F) as well as of the CAF markers and TGF-β 
target genes Fap, Ctgf, and Pai1 (Supplemental Figure 6A), indicat-
ing that A2V limits stromal activation in this model.
A2V+aCD40 also downregulated Mmp14 expression and pro-
moted even greater destruction of the stroma, compared with A2V 
monotherapy in the desmoplastic APP tumors, as shown by both 
reduced stromal cell proliferation and content (Figure 6, B and G). 
Altogether, these results demonstrate that dual blockade of VEGFA 
and ANGPT2, especially in combination with aCD40, normalizes 
tumor blood vessels and reduces tumor fibrosis.
Combined A2V and aCD40 antibody therapy promotes intraep-
ithelial infiltration of cytotoxic CD8+ T cells. We next analyzed 
tumor-infiltrating lymphocytes (TILs). Although neither mono-
therapy had significant effects on the total number of intratumoral 
CD8+ or CD4+ T cells (Supplemental Figure 6B), we found that 
A2V+aCD40 promoted the influx of CD8+ T cells and increased 
the CD8/CD4 ratio in APP tumors (Figure 6, H and I, and Supple-
mental Figure 6B).
Engagement of CD8+ T cells with epithelial cells is strongly 
associated with a favorable prognosis in CRC (51). We therefore 
characterized the spatial distribution of T cells within tumors. 
A2V+aCD40 markedly induced intraepithelial infiltration of 
CD8+ T cells into both AP and APP tumors (Figure 6, H and I). 
Most important, the combined treatment dramatically increased 
the proportion of granzyme B+ (GZMB+) CD8+ T cells, which is 
indicative of an activated cytotoxic phenotype, in APP tumors; a 
similar but less marked response was observed in AP tumors (Fig-
ures 6J and Supplemental Figure 6C). Tregs suppress effector T 
cells, and a high CD8+/Treg cell ratio is generally associated with 
a favorable prognosis in solid cancers (52). In both tumor models, 
A2V strongly reduced the abundance of intratumoral CD4+Foxp3+ 
Tregs, resulting in a significantly higher CD8+/Treg ratio, an effect 
that was maintained in the A2V+aCD40 group (Figure 6, K and L).
We further analyzed genome-wide transcriptional responses 
of tumors to A2V+aCD40 treatment using gene set enrichment 
analysis (GSEA) (53). The most prominent pathways activated by 
A2V+aCD40 in AP and APP tumors were related to allograft rejec-
tion and IFN signaling (Figure 6M), thus confirming the ability of 
A2V+aCD40 to convert the immunologically “cold-phenotype” 
AP and APP tumors into a highly inflamed state that was poten-
tially conducive to an efficient anticancer immune response. Sur-
prisingly, using signatures for mouse immune cell populations 
(54), we found that, together with the expected increase in DC 
and T cell signatures, A2V+aCD40 treatment also led to enrich-
ment of B cell–associated transcripts, whereas the macrophage 
desmoplastic microenvironment. This prompted us to pursue 
reprogramming of the TME as an alternative therapeutic strategy. 
Previous studies have shown that anticancer immunity can be effi-
ciently triggered through the activation of CD40 in desmoplastic 
pancreatic ductal adenocarcinoma (20, 21). We then used a murin-
ized version of A2V to block both VEGFA and ANGPT2 (49) (17) 
in combination with FGK4.5, an agonistic CD40 (aCD40) anti-
body (50), in genetic models of CRC. We started the treatments 
2 weeks after tumor initiation and terminated the experiments 2 
weeks later (Figure 6A). Treatment with aCD40 had a minor, if 
any, effect on tumor growth in either model, whereas A2V had a 
measurable growth-inhibitory effect on AP but not APP tumors. In 
contrast, the combination of A2V and aCD40 inhibited the growth 
of both AP and APP tumors (Figure 6A). Further microscopic anal-
ysis revealed cancer cell death and an accumulation of p-γH2A.X+ 
nuclear foci specifically in tumors treated with the A2V+aCD40 
combination (Figure 6, B and C, and Supplemental Figure 5, A and 
B). Similarly, cancer cell proliferation was significantly reduced 
only by the combination treatment in both models (Figures 6C). 
Together, these results demonstrate that the combination of A2V 
and aCD40 had marked antitumoral activity in both AP and che-
moresistant APP models.
Combined A2V and aCD40 antibody therapy normalizes tumor 
blood vessels and reduces fibrosis. We next examined the effects 
of treatments on tumoral vascular density, vessel caliber, mural 
cell coverage, tumor hypoxia, and CAF activation and prolifer-
ation. A2V did not alter the relatively sparse vascular network of 
AP tumors, whereas it pruned the angiogenic vasculature of APP 
tumors (Figure 6, D and E). In both tumor models, A2V and the 
Figure 5. The PROX1 target MMP14 recapitulates tumor desmoplasia, 
angiogenesis, and chemoresistance. (A) Mmp14 and Anxa1 expression in 
organoids and tumors. qRT-PCR data were normalized to the AKP organ-
oids or the mean of AP tumors. (B) MMP14 and ANXA1 expression in CRC 
CMS classification (GSE39582; n = 409). P < 0.001, by 1-way ANOVA with 
Tukey’s multiple comparisons test. (C) 5-FU effect on WNT targets and 
profibrotic factors. A heatmap of the indicated genes is shown (n = 3). (D) 
Tumor growth and weights after overexpression of MMP14 or ANXA1. Fifty 
MMP14-AKP, ANXA1-AKP, or control dlNGFR-AKP organoids were implant-
ed s.c. per mouse (n = 6). (E) MMP14 overexpression promoted desmopla-
sia. Images in top row show Masson’s trichrome staining; images in bot-
tom row show staining for PH3 (green), α-SMA (red), E-cadherin (white), 
and DNA (blue). Scale bars: 50 μm. (F) Quantification of stromal content, 
stromal and cancer cell proliferation, and vascular density in control and 
MMP14- or ANXA1-overexpressing tumors. Data are presented as the fold 
change versus the AKP control mean or versus the MMP14 mean for stro-
mal proliferation. (G) MMP14-AKP tumors were chemoresistant. Mice were 
implanted s.c. with 50 control dlNGFR-AKP or 100 MMP14-AKP organoids 
(n = 8). 5-FU treatment was started when tumors reached 100 mm3 in size. 
(H) 5-FU effect on desmoplasia and stromal MMP14 expression in MMP14-
AKP tumors. Quantification of α-SMA+ stromal area and MMP14+α-SMA+ 
coexpression in control dlNGFR-AKP and MMP14-AKP tumors. Data are 
presented as the fold change versus the AKP control mean. (I) 5-FU effect 
on angiogenesis in MMP14-AKP tumors. VE-cadherin+ vessel density is 
presented as the fold change versus the AKP control mean. (J) Effect of 
5-FU on angiogenesis in MMP14-AKP tumors. Images show staining for 
VE-cadherin (green), α-SMA (red), E-cadherin (white), and DNA (blue). 
Scale bars: 50 μm. Data represent the mean ± SD. *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001, and ****P ≤ 0.0001, by Student’s t test (A) or 1-way ANOVA 
(scatterplots) or 2-way ANOVA (growth curves) with Tukey’s multiple com-
parisons test. D, dlNGFR; A, Annexin A1; M, MMP14.
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and Supplemental Figure 7A). Because A2V+aCD40 in combina-
tion with T cell elimination was poorly tolerated, the mice had to 
be euthanized after a short treatment window, with only modest 
effects on tumor growth observed (Figures 7A and Supplemental 
Figure 7, B and C).
Analysis of draining lymph nodes confirmed that A2V+aCD40 
activated DCs, as determined by increased expression of the 
costimulatory receptor CD86, and promoted the accumulation of 
CD8+ T cells in both tumor models (Figure 7B). We also observed 
an expansion of splenic CD8+CD44+CD62l+ memory T (Tm) cells, 
suggestive of long-lasting effector function. In addition to increas-
ing the number of intraepithelial CD8+ T cells, A2V+aCD40 
enhanced the accumulation of CD8+ IFN-γ+GZMB+ CTLs and 
increased the expression of the CTL markers perforin (Prf1) and 
granzyme A (Gzma) in the tumors. As expected, T cell elimination 
abated expression of the T cell response markers (Figure 7C and 
Supplemental Figure 7, D–F). Most important, T cell elimination 
fully rescued cancer cell proliferation and abolished cell death in 
response to A2V+aCD40 (Figure 7, D and E).
Loss of T cells did not alter the changes in vascular pruning 
or caliber or the mural coverage of APP tumors in response to 
A2V+aCD40 (Figure 7F and Supplemental Figure 7G), indicating 
that TILs do not mediate A2V-induced vascular normalization. 
Finally, the attrition of tumor stroma induced by A2V+aCD40, 
as analyzed by staining for α-SMA and expression of the TGF-β 
targets Pai1 and Ctgf, was also largely T cell independent (Figure 
7G and Supplemental Figure 7H). Overall, our results indicate 
that the antitumoral activity of A2V+aCD40 is mostly mediated 
by T cells in genetic mouse models of MSS CRC, although addi-
tional mechanisms must be involved in therapy-induced stromal 
remodeling and destruction.
Finally, we gauged the requirement of ANGPT2 blockade 
for A2V+aCD40 therapeutic efficacy. We used B20, a VEGFA- 
blocking antibody equivalent to bevacizumab (58). A2V+aCD40 
but not B20+aCD40 promoted infiltration of intratumoral CD8+ 
T cells and induced significant cell death in size-matched AP and 
APP tumors (Figure 7, H and I). Although no differences were 
found in blood vessel density (data not shown), only A2V+aCD40 
increased blood vessel caliber (indicative of normalization) and 
depleted the tumor stroma (Supplemental Figure 7I). These results 
indicate that double blockade of ANGP2 and VEGFA is more effi-
cient in promoting immune activation and cancer cell destruction.
Overall, our results present a model in which vascular normal-
ization by A2V prevents the accumulation of immunosuppressive 
Tregs and facilitates the formation of TLSs, which may function as 
additional sites of naive T cell infiltration and T cell priming (55). 
Although such effects were not sufficient to induce significant 
cancer cell killing per se, the combination with a CD40 agonist 
enabled antigen-presenting cell activation and the destruction of 
cancer cells by CTLs (Figure 7J).
Discussion
The molecular mechanisms that drive the emergence of pheno-
typically distinct CRC subtypes and their differential responses 
to therapies are currently under intense investigation. Although 
adjuvant chemotherapy increases overall survival, many 
patients either do not respond to treatment or relapse. Recent 
signature was not affected (Supplemental Figure 6D). Therefore, 
we analyzed the distribution of intratumoral B cells by staining 
B220 in control (IgG-treated) tumors compared with treated 
tumors. We observed few and sparse B cells in both control- and 
aCD40-treated tumors. Interestingly, we found an increased inci-
dence of large peri- and intratumoral B cell clusters in A2V- and 
A2V+aCD40-treated tumors (Supplemental Figure 6, E–G). Such 
clusters harbored both B and T cells and contained HEV-like 
vessels lined with plump ECs (Supplemental Figure 6G). These 
results demonstrate that A2V promoted the generation of tertiary 
lymphoid structures (TLSs), which are nonencapsulated immune 
cell aggregates that are associated with productive antitumor 
immunity and a favorable prognosis in many cancer types, includ-
ing CRC (55). Taken together, our results demonstrate that A2V 
profoundly reprogrammed the TME in mouse models of CRC and 
potentiated immune activation in response to aCD40 signaling.
The antitumoral activity of A2V+aCD40 is T cell and ANGPT2 
dependent. Agonistic CD40 antibodies activate antigen-present-
ing cells and promote antitumoral, T cell–dependent responses. 
They also induce tumoricidal macrophages that were shown to 
control tumors by promoting tumor stroma destruction in the 
absence of T cell immunity (20, 56, 57). We then asked whether 
the antitumoral activity of A2V+aCD40 is T cell dependent. 
To this aim, we induced concomitant depletion of T cells using 
α-CD8a and α-CD4 antibodies (Figure 7A). We achieved efficient 
T cell ablation from tumors, as determined by staining of tumor 
sections with noncompeting α-CD8 and α-CD4 antibodies, or by 
FACS analysis of draining lymph nodes using α-CD3 (Figures 7A 
Figure 6. A2V+aCD40 combination reduces AP and APP tumor growth. 
(A) Treatment scheme and weights of tumors in the indicated conditions. 
AP IgGs, AP A2V, or AP A2V+aCD40, n = 10; AP aCD40, n = 8; APP IgGs, 
APP A2V or APP A2V+aCD40, n = 7; APP aCD40, n = 6. (B) A2V+aCD40 
induced tumor necrosis and stromal destruction. Images show staining for 
E-cadherin (white), PH3 (green), and α-SMA (red). Scale bars: 50 μm. (C) 
Quantification of tumor necrosis and proliferation. Necrosis is indicat-
ed by the percentage of necrotic glands. Proliferation was quantified by 
PH3+E-cadherin+ tumor cells normalized to total E-cadherin+ and the AP 
IgGs mean. (D) A2V and A2V+aCD40 promoted vascular maturation. Images 
show staining for CD31 (green) and α-SMA (red). Scale bars: 50 μm. (E) 
Quantification of vessel density, mural coverage, and vessel caliber. Data 
were normalized to the AP IgGs mean. (F) A2V and A2V+aCD40 reduced 
desmoplasia. The α-SMA+ stromal area was normalized to the correspond-
ing tumor area and the AP IgGs mean. (G) A2V and A2V+aCD40 effects on 
stromal proliferation and Mmp14 mRNA. Quantification of PH3+α-SMA+ 
fibroblasts per tumor area and qRT-PCR for Mmp14 in tumor lysates. Data 
were normalized to the AP IgGs mean. (H) A2V+aCD40 promoted CD8+ T 
cells intraepithelial infiltration. Images show staining for CD8a (green), 
VE-cadherin (red), and E-cadherin (white). Scale bars: 50 μm. (I) CD8+/CD4+ 
TIL ratio and intraepithelial CD8+ T cell quantification were determined as 
the fold change versus the AP IgGs mean. (J) A2V+aCD40 increased GZMB+ 
cytotoxic CD8+ T cells. Intratumoral CD8+GRZB+ T cells were normalized 
to CD8+ T cells and the AP IgGs mean. (K) A2V and A2V+aCD40 reduced 
Tregs. Images show staining for Foxp3 (green), CD4 (red), and E-cadherin 
(white). Scale bars: 50 μm. (L) Quantification of Tregs and CD8+/Treg ratio. 
CD4+Foxp3+ expression was normalized to CD4+ T cells and the AP IgGs 
mean. (M) Pathways deregulated by A2V+aCD40, AP A2V+aCD40, or APP 
A2V+aCD40, n = 4; AP or APP controls, n = 6. FDR <0.05. NES, normalized 
enrichment scores. Data represent the mean ± SD. *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001, and ****P ≤ 0.0001, by 1-way ANOVA with Tukey’s multiple 
comparisons test.
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still slowly proliferate but also promote TGF-β–dependent stromal 
activation and angiogenesis (Figure 7J).
High stromal content also fosters the chemoresistant pheno-
type of Prox1-defcient tumors, because chemotherapy fuels stro-
mal cell activation and angiogenesis, which then support the sur-
vival of tumor cells. Interestingly, 5-FU enhanced the growth of 
orthotopic APP tumors, whereas the growth of s.c. tumors was not 
affected. Of note, the site of tumor implantation may influence 
tumor growth and its response to therapy (63). Furthermore, der-
mal and intestinal fibroblasts display distinct responses to cyto-
kines (64), thus they may differentially contribute to the tumor 
response to chemotherapy.
Mechanistically, MMP14, which is repressed by PROX1 (ref. 48 
and this study), recapitulated several features of Prox1-deficient 
tumors, including desmoplasia, angiogenesis, and chemoresis-
tance. MMP14 promotes invasion in several cancers through its 
ability to degrade collagen and other ECM components (65), 
thus the increased fibrosis in MMP14-AKP tumors may appear 
counterintuitive. However, MMP14 also promotes fibrosis by 
cleaving latent TGF-β. Thus, the function of MMP14 in the TME 
is more complex and may include not only ECM degradation 
but also enhanced release of profibrotic factors and ECM pro-
duction and assembly. Of note, inhibition of MMP14 reduced 
TGF-β production and increased tumor perfusion in breast car-
cinoma models (66), and we observed a strong potentiation of 
MMP14 expression in both cancer and stromal cells in response to 
chemo therapy, along with enhanced fibrosis. Antibody-mediated 
MMP14 blockade has shown promising results in limiting the 
progression of mammary tumor models (66). In the future, it will 
be interesting to explore the clinical relevance of our findings 
by studying whether MMP14 inhibition sensitizes APP tumors 
to 5-FU or further potentiates the antitumoral activity resulting 
from aCD40+A2V treatment.
In our search for an alternative treatment for chemoresistant 
CRC, we investigated the potential of immune therapy. Block-
ade of PD-1/PD-L1 signaling targets exhausted CD8+ T cells. It is 
effective in highly mutated MSI CRCs, in which the T cell response 
has already been elicited (67, 68). To date, all immune interven-
tions, including PD-1/PD-L1 checkpoint blockade, adoptive T cell 
transfer, and vaccination, have failed in human MSS CRCs. The 
specific cellular and molecular mechanisms are only beginning to 
be understood. Notably, in mouse MSS intestinal tumors, which 
are unresponsive to α–PD-1 therapy, blockade of TGF-β was able 
to initiate a productive T cell response (14). Here, we investigated 
an alternative combinatorial approach that targeted tumor blood 
vessels and CD40 signaling. CD40L/CD40 is a costimulatory 
pathway that promotes antigen-presenting cell activation and 
CD8+ T cell–mediated antitumor immunity (21, 57). While PD-1 
blockade induces tumor rejection by restoring the activity of 
exhausted CD8+ effector T cells, stimulation of CD40 activates 
DCs and enhances T cell priming. Moreover, CD40 activation also 
directly boosts tumor-specific CD8+ T cell immunity and thus may 
be complementary to immune checkpoint blockade approaches 
(57, 69). Our results show that the antitumor efficacy of aCD40 
monotherapy is limited, as observed in other tumor models and 
in clinical trials (20, 56, 70). In contrast, additional blockade of 
VEGFA and ANGPT2, a vessel-destabilizing ligand of TIE2 and a 
clinical evidence indicates that epithelium-rich tumors with 
high WNT signaling respond best to chemotherapy, whereas 
outcomes are worst for patients with desmoplastic CRC (7, 10, 
11). Increased TGF-β signaling or Notch hyperactivation has 
been shown to promote desmoplasia in CRC models (14, 47, 59), 
indicating that multiple pathways contribute to stromal expan-
sion in a subset of MSS CRCs.
Here, we show that high expression of PROX1 correlated with 
lower stromal content in human CRC. Prox1 inactivation was 
sufficient to promote tumor fibrosis, angiogenesis, and chemore-
sistance in the genetic model of CRC. Interestingly although the 
same APC mutations were present in all cancer cells, areas with 
both high and low intratumoral WNT signaling were observed in 
mouse and human APC-mutant tumors (this study and ref. 60), 
indicating that additional mechanisms control WNT activation in 
CRC. PROX1 is induced in CRC cells only in response to a high 
and sustained WNT activation (22). Conversely, we report here 
that loss of Prox1 blunted WNT activity and increased the produc-
tion of multiple profibrotic factors, including TGF-β1 and MMP14. 
Of note, Notch hyperactivation reduces PROX1 expression (61) 
and generates desmoplastic, invasive CMS4-like tumors with high 
TGF-β signaling (59), whereas PROX1 suppresses Notch signal-
ing in colon cancer cells (62). Taken together, these observations 
suggest a model in which fluctuations of intratumoral Notch and 
WNT activity, if sufficient to switch off PROX1, will initiate a con-
version toward a distinct tumor phenotype, in which cancer cells 
Figure 7. A2V+aCD40 antitumor activity is T cell dependent. (A) Tumors 
were treated with control mAbs, A2V+aCD40, or A2V+aCD40+α-CD8+α-
CD4. Quantification of intratumoral T cells was determined by the fold 
change versus the AP IgGs mean. AP IgGs, n = 8; AP A2V+aCD40 AP 
A2V+aCD40+αCD8+αCD4 or APP A2V+aCD40, n = 9; APP IgGs, n = 10; 
APP A2V+aCD40+αCD8+αCD4, n = 7. (B) FACS analysis of lymph node 
CD11b+CD11c+CD86+ DCs and CD11b–B220–MHCII–CD8+ T cells and splenic 
CD11b–B220–MHCII–CD8a+CD44+CD62l+ Tm cells. (C) Quantification of intra-
tumoral cytotoxicity. Quantification of CD11b–CD3+CD8a+IFN-γ+ and GZMB+ 
T cells, percentage of CD45+ cells, and qRT-PCR analysis of Prf1 and Gzma 
expression, normalized to the AP of IgGs mean. (D) T cells mediated cancer 
cell death in A2V+aCD40-treated tumors. Cell death was determined by 
the percentage of necrotic glands. PH3+E-cadherin+ cells were normalized 
to the AP IgGs mean. (E) Effect of T cell depletion on tumor cell death and 
stroma. Images show staining for PH3 (green), α-SMA (red), E-cadherin 
(white), and DNA (blue). Scale bars: 50 μm. (F) Quantification of vessel 
density and mural coverage. Data were normalized to the AP IgGs mean. 
(G) A2V+aCD40 reduced stromal content after T cell depletion. Quan-
tification of stromal content and proliferation is shown, and data were 
normalized to the AP IgGs mean. (H) Comparison of A2V+aCD40 versus 
A2V+B20 combination treatment. Images show staining for CD8a (green), 
VE-cadherin (red), E-cadherin (white), and DNA (blue). AP IgGs, n = 10; AP 
B20+aCD40 or AP A2V+aCD40, n = 11; APP IgGs or APP B20+aCD40, n = 8; 
APP A2V+aCD40, n = 9. Scale bars: 50 μm. (I) Quantification of CD8+ T cell 
infiltration and cell death. Cell death was determined by the percentage 
of necrotic tumor glands. CD8a+ T cell infiltration was determined by the 
fold change versus the AP IgGs mean. (J) PROX1hi tumors display high WNT 
signaling, a small amount of stroma, and are chemosensitive. Low PROX1 
levels blunt WNT activation and promote tumor desmoplasia, angiogene-
sis, and chemoresistance. A2V+aCD40 normalizes the tumor vasculature, 
reduces Treg numbers, expands TLSs, and induces antitumor responses. 
Data represent the mean ± SD. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and 
****P ≤ 0.0001, by 1-way ANOVA with Tukey’s multiple comparisons test. 
Comb., combination; Tdepl., T cell depletion.
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by suppressing the antitumor activity of CTLs. Here, we propose 
that relieving Treg-mediated immunosuppression in combination 
with the activation of CD8+ T cell function by aCD40 underlies the 
enhancement of T cell immunity by A2V+aCD40.
The destruction of tumor fibrosis, and in particular periepi-
thelial CAFs, by A2V+aCD40 is likely an important additional 
factor that facilitates engagement of CTLs with cancer cells and 
increases therapeutic efficacy. The attrition of tumor stroma by 
A2V+aCD40 was T cell independent, hence, additional mecha-
nisms such as IFN-γ–dependent reprogramming of tumor-associ-
ated macrophages may be responsible for stromal remodeling by 
A2V+aCD40, as observed previously in the desmoplastic PDAC 
model treated with aCD40 (56). Vascular normalization by A2V 
also promoted the formation of intra- and peritumoral TLSs. The 
presence of TLSs is a generally favorable prognostic factor in 
human cancers, and they enhance the local antitumor immune 
response by providing a site for the homing and activation of naive 
T cells (79). TLSs have the advantage of concentrating immune 
cells and promoting an immune response in close proximity to 
cancer cells, which might complement or even circumvent the 
need for immune cell trafficking between the tumor and second-
ary lymphoid organs. Angiogenic blockade or the direct delivery 
of the lymphotoxin β receptor ligand LIGHT to tumor vessels in 
a genetic model of pancreatic neuroendocrine tumor promoted 
the formation of HEV-like vessels or de novo formation of TLSs 
and improved the response to immune therapies (18, 19). Alto-
gether, our results provide further evidence that vascular normal-
ization by A2V preconditions the TME for improved T cell pene-
tration and function.
In summary, our results uncover a mechanism underlying 
chemoresistance in CRC by showing that low PROX1 expression 
in Apc-mutant cancer cells generates desmoplastic and chemo-
resistant tumors. We further propose that chemotherapy is poten-
tially harmful in patients with desmoplastic tumors, as in mouse 
models, it led to TGF-β– and MMP14-dependent stromal activa-
tion and angiogenesis and fostered a cancer-supporting stromal 
microenvironment. We also show that simultaneous vascular 
normalization by A2V and immune activation by aCD40 had sub-
stantial therapeutic activity and efficiently inhibited both chemo-
sensitive and chemoresistant Apc-mutant intestinal tumors. We 
believe these results call for further investigation of this therapeu-
tic approach in human MSS CRCs.
Methods
A detailed description of the methods is available in the Supplemental 
Methods.
Statistics. Statistical analysis was performed using GraphPad 
Prism 6 for MacOS (GraphPad Software). A Student’s t test or ordi-
nary 1-way or 2-way ANOVA with Tukey’s multiple comparisons test 
was performed, with the 1-way ANOVA used for grouped comparisons 
and 2-way ANOVA for pairwise comparisons. Linear regression with a 
95% CI was used to evaluate correlations between 2 variables. Unless 
otherwise specified, all ex vivo and in vitro data are represented by 
scatter dot plots with the mean ± SD, where each individual mouse or 
cell population repeat is represented by a single dot. In vivo tumor vol-
ume growth curves represent the mean value of all individuals from a 
group ± SD, at each time point. All in vitro analyses were repeated at 
regulator of blood vessel maturation, potently increased the ability 
of aCD40 to stimulate an antitumor immune response. In preclin-
ical models of breast cancer, the blockade of ANGPT2 potentiates 
the effects of VEGFA inhibition on tumor growth, inhibits metas-
tasis, and sensitizes tumors to PD-1 checkpoint blockade (17). Our 
results indicate that double blockade of ANGPT2 and VEGFA is 
also more effective than α-VEGFA in promoting immune activa-
tion and cancer cell destruction in CRC models in response to 
CD40 activation.
Systemic aCD40 therapy is associated with dose-limiting tox-
icities (refs. 71, 72 and this study, Supplemental Figure 7B), there-
fore, we were unable to evaluate whether repeated administration 
of A2V+aCD40 could suppress tumor growth for more extended 
time periods. Intratumoral- or ECM-targeted delivery of aCD40 
antibodies proved highly effective and devoid of systemic toxicity 
in s.c. sarcoma and melanoma models (72, 73). These studies pro-
vide a rationale for testing tumor-targeted aCD40 antibodies and 
evaluating the long-term benefits of the combined treatment in our 
CRC models. Also, an important question relates to the cell type(s) 
targeted by the aCD40 antibody in AP and APP models. Previ-
ous studies documented the important role of CD40 in tumor- 
associated macrophages, DCs (71), and B cells (74). Interest ingly, 
we found that in both AP and APP tumors, CD40 was promi-
nently expressed in a subset of normal and cancer-associated 
fibroblasts, suggesting that these cells may potentially contribute 
to the antitumor activity of aCD40 (Supplemental Figure 8).
Antiangiogenic blockade affects tumor immunity on several 
levels. Vascular normalization improves the alignment of ECs and 
pericytes and vessel functionality and promotes CTL infiltration 
and activity by increasing the expression of endothelial adhesion 
receptors for T cell trafficking, thereby reducing hypoxia and reliev-
ing high interstitial fluid pressure (75). In addition, enhanced tumor 
cell death caused by an insufficient supply of oxygen and nutrients 
upon angiogenesis inhibition and the subsequent release of tumor- 
associated antigens may stimulate antitumor immune responses. 
We observed no effect (AP model) or a modest decrease (APP mod-
el) in the vascular density of A2V-treated tumors, and A2V alone 
had no significant effect on tumor cell proliferation or tumor necro-
sis. Furthermore, both AP and APP tumors displayed low hypoxia, 
which was not increased after antiangiogenic therapy. These obser-
vations argue that dual VEGFA and ANGPT2 blockade in these CRC 
models does not alter vascular perfusion or intratumoral hypoxia, 
but rather enhances the maturation of the tumor vascular network 
in a manner that promotes better lymphocyte trafficking through, 
for example, increased expression of lymphocyte chemokines or 
adhesion receptors by endothelial or mural cells.
Indeed, the most consistent effects of A2V in both models 
were an enhanced recruitment of pericytes, the formation of TLSs, 
reduced stromal activation, an accumulation of Tregs,  and an 
increased infiltration of CTLs. The role of Tregs in human CRC is 
controversial: high intratumoral Treg density has been associated 
with better outcomes (76, 77), whereas other data indicate that 
Tregs promote protumor Th17 responses and suppress tumor- 
specific CD8+ T cell activation in patients with CRC (78). It is pos-
sible that Tregs play a beneficial, anticancer role by reducing local 
inflammation in the absence of immune therapy, whereas in the 
presence of immune activation by aCD40, they become harmful 
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